253 related articles for article (PubMed ID: 28699105)
1. Tapentadol in neuropathic pain cancer patients: a prospective open label study.
Galiè E; Villani V; Terrenato I; Pace A
Neurol Sci; 2017 Oct; 38(10):1747-1752. PubMed ID: 28699105
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
[TBL] [Abstract][Full Text] [Related]
4. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
5. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients.
Jung JY; Chon HJ; Choi YJ; Yeon SE; Choi SY; Lee KH
Support Care Cancer; 2022 Jul; 30(7):6103-6112. PubMed ID: 35420330
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Effects of Opioid Switching to Tapentadol - Retrospective Analysis of Efficacy and Adverse Effects].
Homma M; Kokubun H; Hayashi N; Kanai A; Atsuda K
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1081-1086. PubMed ID: 30042277
[TBL] [Abstract][Full Text] [Related]
7. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
8. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
10. Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.
Mercadante S; Porzio G; Adile C; Aielli F; Cortegiani A; Dickenson A; Casuccio A
Curr Med Res Opin; 2014 Oct; 30(10):2063-8. PubMed ID: 24926734
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol in cancer pain management: a prospective open-label study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Adile C; Ficorella C; Giarratano A; Casuccio A
Curr Med Res Opin; 2012 Nov; 28(11):1775-9. PubMed ID: 23057488
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
13. High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies.
Rossignol J; Cozzi B; Liebaert F; Hatton S; Viallard ML; Hermine O; Greco C
Support Care Cancer; 2019 Aug; 27(8):3053-3059. PubMed ID: 30607681
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.
Baron R; Kern U; Müller M; Dubois C; Falke D; Steigerwald I
Pain Pract; 2015 Jun; 15(5):471-86. PubMed ID: 24750558
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan.
Sugiyama Y; Kataoka T; Tasaki Y; Kondo Y; Sato N; Naiki T; Sakamoto N; Akechi T; Kimura K
Jpn J Clin Oncol; 2018 Apr; 48(4):362-366. PubMed ID: 29506199
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
Orszaghova Z; Galikova D; Lesko P; Obertova J; Rejlekova K; Sycova-Mila Z; Palacka P; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M; Chovanec M
Clin Genitourin Cancer; 2024 Jun; 22(3):102067. PubMed ID: 38555680
[TBL] [Abstract][Full Text] [Related]
17. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.
Smith EML; Zanville N; Kanzawa-Lee G; Donohoe C; Bridges C; Loprinzi C; Le-Rademacher J; Yang JJ
Support Care Cancer; 2019 Jul; 27(7):2599-2608. PubMed ID: 30460399
[TBL] [Abstract][Full Text] [Related]
18. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of Tapentadol for Neuropathic Pain in Cancer].
Takahara Y; Tanahashi J; Murota K; Imai M; Takagi Y; Kimata T
Gan To Kagaku Ryoho; 2021 Jun; 48(6):811-814. PubMed ID: 34139729
[TBL] [Abstract][Full Text] [Related]
20. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
Alberti P; Rossi E; Cornblath DR; Merkies IS; Postma TJ; Frigeni B; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; Cavaletti G;
Ann Oncol; 2014 Jan; 25(1):257-64. PubMed ID: 24256846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
